Skip to main content Skip to search Skip to main navigation

EMA: New Q&As for Wholesale Distributors/Brokers on Suspicious Offers

The EMA has published two new GDP Q&As for wholesale distributors and brokers on suspicious offers.

How will distributors and brokers know if they are given suspicious offers?
Wholesalers must be aware of the risk of receiving falsified or substandard medicinal products. Guidance from EU GDP Guidelines suggests conducting "due diligence" checks when contracting new suppliers, considering factors such as the supplier’s reputation, offers of medicinal products likely to be falsified, large or unusual offers, and abnormal pricing (see article 5.2 EU GDP Guidelines).
Suspicious offers may include:

  • Products in high demand or supply shortages
  • Communication through unconventional channels (e.g., WhatsApp)
  • Urgency or unusually low prices
  • Products with decommissioned identifiers or broken tamper-evident features
  • Suppliers not listed in official databases (EudraGMDP for wholesalers, national repositories for brokers)
  • Unverified availability or unexpected economic/geographical offers

Wholesalers must only obtain products from authorised entities, as specified in EU regulations. Products imported from third countries require a manufacturing/import authorisation.

What should wholesale distributors and brokers do if they learn of suspicious offers?
Wholesalers or brokers who encounter a suspicious offer must immediately contact the national competent authority and the marketing authorisation holder. This applies whether they are directly offered suspected falsified products or become aware of such offers to others, including when verifying unique identifiers for others.


Source:

EMA: Guidance on good manufacturing practice and good distribution practice: Questions and answers

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next? NEU

Purified Water – The new Chinese Pharmacopoeias and What Happens Next? NEU

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
What are the requirements for gas distribution systems?

What are the requirements for gas distribution systems?

You can view the answer here:
Read more
What are the quality requirements for pharmaceutical gases?

What are the quality requirements for pharmaceutical gases?

You can view the answer here:
Read more
EMA: Update on the Guideline “Stability Testing for Variations”

EMA: Update on the Guideline “Stability Testing for Variations”

The EMA has updated the guideline on stability testing for variations (Revision 3, applicable from 15 January 2026).
Read more
Previous
Next